108552
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
贝伐珠单抗/信迪利单抗/仑伐替尼三联疗法对多灶性难治性乙肝相关肝细胞癌的持久控制
Authors Wang J, Wang J, Chen J
Received 20 June 2025
Accepted for publication 8 September 2025
Published 13 September 2025 Volume 2025:17 Pages 1981—1987
DOI https://doi.org/10.2147/CMAR.S547885
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Professor Bilikere Dwarakanath
Jian Wang,1 Junhui Wang,2 Jianxin Chen3
1Department of International Ward, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People′s Hospital, Quzhou, Zhejiang, 324000, People’s Republic of China; 2Department of Radiation Oncology, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People′s Hospital, Quzhou, Zhejiang, 324000, People’s Republic of China; 3Department of Medical Oncology, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People′s Hospital, Quzhou, Zhejiang, 324000, People’s Republic of China
Correspondence: Jianxin Chen, Email cjx8137@163.com
Background: Advanced HCC progressing after standard first-line immune checkpoint inhibitor (ICI)/antiangiogenic therapy and second-line tyrosine kinase inhibitors (TKIs) has limited treatment options.
Case Presentation: A 67-year-old male with HBV-related HCC (cT2N1M0, Child-Pugh B) exhibited rapid progression after transarterial chemoembolization, bevacizumab/sintilimab, and lenvatinib monotherapy. Salvage triplet therapy with bevacizumab (400 mg IV q3w), sintilimab (200 mg IV q3w), and lenvatinib (8 mg daily) achieved > 50% alpha-fetoprotein (AFP) reduction within two cycles and sustained radiologic disease stabilization for 10 months, with only grade 1 fatigue and hemoptysis.
Conclusion: This is the first documented case of bevacizumab/sintilimab/lenvatinib triplet efficacy in triple-class refractory HCC, suggesting potential synergistic mechanisms and feasibility even in Child-Pugh B patients. These findings warrant further investigation in prospective studies.
Keywords: hepatocellular carcinoma, multi-refractory HCC, triplet therapy, salvage therapy, disease control
1Department of International Ward, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People′s Hospital, Quzhou, Zhejiang, 324000, People’s Republic of China; 2Department of Radiation Oncology, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People′s Hospital, Quzhou, Zhejiang, 324000, People’s Republic of China; 3Department of Medical Oncology, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People′s Hospital, Quzhou, Zhejiang, 324000, People’s Republic of China
Correspondence: Jianxin Chen, Email cjx8137@163.com
Background: Advanced HCC progressing after standard first-line immune checkpoint inhibitor (ICI)/antiangiogenic therapy and second-line tyrosine kinase inhibitors (TKIs) has limited treatment options.
Case Presentation: A 67-year-old male with HBV-related HCC (cT2N1M0, Child-Pugh B) exhibited rapid progression after transarterial chemoembolization, bevacizumab/sintilimab, and lenvatinib monotherapy. Salvage triplet therapy with bevacizumab (400 mg IV q3w), sintilimab (200 mg IV q3w), and lenvatinib (8 mg daily) achieved > 50% alpha-fetoprotein (AFP) reduction within two cycles and sustained radiologic disease stabilization for 10 months, with only grade 1 fatigue and hemoptysis.
Conclusion: This is the first documented case of bevacizumab/sintilimab/lenvatinib triplet efficacy in triple-class refractory HCC, suggesting potential synergistic mechanisms and feasibility even in Child-Pugh B patients. These findings warrant further investigation in prospective studies.
Keywords: hepatocellular carcinoma, multi-refractory HCC, triplet therapy, salvage therapy, disease control